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ABSTRACT 
Background: Human rabies is an ongoing significant public health problem in 
many developing countries, with India reporting the highest incidence of rabies- 
related eaths @20,000 per year). Many people living in India cannot afford the 
standard IM postexposure prophylaxis (PEP) with cell-culture vaccines, which 
are administered using a 5-dose regimen developed in Essen, Germany. A po- 
tentially less expensive intradermal (ID)regimen, based on the Essen regimen, 
has been developed at the Kempegowda Institute of Medical Sciences (KIMS), 
Bangalore, India. 
Objective: The objective of this study was to compare the immunogenicity 
and local and systemic tolerability of the KIMS-ID regimen with those of the 
standard Essen IM regimen in healthy adult volunteers in India. 
Methods: This randomized, open-label, active-controlled trial was con- 
ducted at the Antirabies Clinic, Medical College, KIMS. Healthy adult volunteers 
were randomly assigned to receive purified chick embryo cell vaccine (PCECV) 
using the KIMS-ID regimen (0.1 mL injected ID at 2 body sites on days 0, 3, 7, 14, 
and 28 ["2-2-2-2-2"]) or the Essen IM regimen (1 mL injected IM at 1 body site on 
the same days ["1-1-1-1-1"]). Subjects were followed up for 365 days by the treat- 
ing physician and encouraged to voluntarily report any adverse events (AEs). 
Serum rabies virus-neutralizing antibody (RVNA) concentrations were mea- 
sured before the first injection on day 0 (baseline) and on days 14, 28, 90, 180, 
and 365, using the rapid fluorescent focus inhibition test. 
Results: Ninety-one subjects were enrolled and included in the tolerability 
and immunogenicity analyses. The ID group comprised 45 subjects (26 men, 19 
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women; mean [SD] age, 20.84 [1.48] years); the IM group, 46 subjects (28 men, 
18 women; mean [SD] age, 21.02 [1.16] years). The most common local AEs were 
pain at the injection site (2/225 [0.9%] in the ID group and 10/230 [4.3%] in the 
IM group; P< 0.006) and itching at the injection site (5/225 [2.2%] in the ID group 
and none in the IM group; P = 0.026). All of the AEs were transient and resolved 
without the need for medication. All subjects had serum RVNA concentrations 
20.5 IU/mL--considered protective by the World Health Organization--at ll follow- 
up visits. However, the mean RVNA concentrations in the IM group were sig- 
nificantly higher compared with those in the ID group from days 14 to 365 (all, 
P < 0.001). 
Conclusion: In this study in healthy volunteers, PEP with PCECV adminis- 
tered using the KIMS-ID regimen was well tolerated and immunologically effica- 
cious for 365 days. Adequate RVNA levels were maintained with the KIMS-ID reg- 
imen from days 14 to 365, although these levels were significantly lower than 
those achieved in the group receiving the Essen IM regimen (all, P< 0.001). (Curt 
Ther Res Clin Exp. 2005;66:323-334) Copyright © 2005 Excerpta Medica, Inc. 
Key words: rabies, intradermal rabies vaccination, KIMS-ID regimen, ran- 
domized controlled trial. 
INTRODUCTION 
Human rabies is an ongoing significant public health problem in many develop- 
ing countries, including India. Worldwide, the 1-year incidence of human rabies- 
related deaths is ~55,000, with India reporting the highest incidence. 1 The 
recently concluded national, multicenter rabies survey, conducted by the World 
Health Organization (WHO) and the Association for Prevention and Control of 
Rabies in India, estimated that the 1-year incidence of animal bites in India is 
1.7% of the population, or ~17 million, and that the 1-year incidence of human 
rabies-related deaths is ~20,000. 2 According to the survey, most of these deaths 
occur in males, people living in rural areas, and those of low socioeconomic 
status. 2
However, rabies is preventable by vaccination, and postexposure prophy- 
laxis (PEP) consisting of vaccine and rabies immunoglobulins can be lifesaving, 
even in cases of severe exposure. Sadly, nearly 80% of rabies-related deaths in 
India occur because victims did not receive vaccinations. 
Rabies Vaccinations in India 
The present situation in India is that nerve tissue vaccine (NTV), prepared 
from the sheep brain and popularly known as the Semple vaccine (named after 
Sir David Semple), is used for PEP in government-managed dispensaries and 
hospitals. NTV is administered in doses of 2 to 5 mL SC at 1 body site (anterior 
abdominal wall) QD for 10 or 14 days. However, NTV injections have been found 
to be painful and highly reactogenic. 3 On the other hand, in the private sector, 
cell-culture vaccines (CCVs)--purified chick embryo cell vaccine (PCECV), pu- 
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rifled vero cell rabies vaccine (PVRV), human diploid cell vaccine (HDCV), 
and purified duck embryo vaccine (PDEV)--are used for PEP. CCVs are admin- 
istered at a dose of 0.5 or 1 mL IM, with 5 injections given over 28 days (days 0, 
3, 7, 14, and 28). CCVs have been found to be well tolerated and highly effi- 
cacious. 4Since the introduction of CCVs in India in the 1980s, their coverage 
has gradually improved, and the 1-year incidence of rabies-related deaths de- 
creased from 30,000 in the 1990s to 20,000 in 2003. 2 Because of the pain, neu- 
ropathy, and other complications associated with NTV, the WHO has recom- 
mended its discontinuation and replacement with CCV. 5 As a result, and after a 
petition by animal-rights activists, the Supreme Court of India, in February 2002, 
directed the government of India to replace the NTV with CCV, and NTV is being 
phased out (unpublished ocument, Government of India). 
Cell-Culture Vaccine Regimens 
Essen Regimen 
Currently, the private sector almost exclusively administers IM CCV using 
the Essen regimen, developed in Essen, Germany. Originally, 6 doses of CCV with 
a minimum potency of 2.5 IU per dose were recommended to be administered 
on days 0, 3, 7, 14, 28, and 90. 6 However, in view of the high rate of noncompli- 
ance on day 90 and the satisfactory immune response of a 5-dose schedule, the 
WHO Expert Committee on Rabies advocated an updated Essen regimen (days 
0, 3, 7, 14, and 28 or 30). 7 The Essen regimen has been used in India for the past 
2 decades. 
Thai Red Cross Regimen 
Unfortunately, even with one less dose, most bite victims living in developing 
countries uch as India cannot afford CCV (cost of standard Essen IM regimen, 
US $25). To alleviate this problem, less expensive regimens were developed 
(Table I). One of these consisted of administering 0.1 mL of CCV intra- 
dermally (ID) at 2 body sites (right and left deltoids) on days 0, 3, and 7, and at 
1 body site (right or left deltoid) on days 28 and 90 ("2-2-2-0-1-1"). This regimen was 
developed by the Thai Red Cross (TRC) Society in 1990, s and was approved by the 
WHO in 1992 for use in developing countries. ~However, although several studies 
showed the efficacy and tolerability of the TRC regimen, ~-12 it was found that 
nearly 10% of patients in Thailand did not return for the day-90 booster dose. 13 
Thus, the WHO reviewed the available data and recently approved amodified TRC 
regimen of 0.1 mL of CCV ID at 2 body sites on days 0, 3, 7, and 28 ("2-2-2-0-2"). 14 
Despite the WHO's approval and modification of the TRC regimen, several 
caveats till exist for CCV use in India. First, the administration of CCV by the ID 
route has not yet been approved by the Drugs Controller General of India (DCGI), 
which is the national regulatory authority. Second, the Indian Council of Medical 
Research (ICMR) is currently evaluating the use of certain brands of PCECV, 
PVRV, and PDEV administered according to the original TRC regimen, which 
includes the day-90 booster (personal communication, M.D. Gupte, Director, 
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National Institute of Epidemiology, Chennai, India, 2005). At the time of the pres- 
ent study, no studies of the modified TRC regimen were being conducted in In- 
dia; furthermore, we at the Kempegowda Institute of Medical Sciences (KIMS), 
Bangalore, India, anticipated that the 90<lay booster might have poor compliance 
in India as it did in Thailand. Third, it is reasonable to assume that physicians in 
the private sector will continue to use the Essen regimen because they would 
encounter cases of postexposure only occasionally, and vials of reconstituted 
vaccine must be used within 8 hours or discarded. Thus, there is no advantage in
following an ID schedule in isolated cases of postexposure. There would be a cost 
advantage only if several cases of postexposure were to be vaccinated ID at 
around the same time of day or at least on the same day, as happens at antirabies 
clinics and hospitals. Finally, assuming that the original TRC regimen will be intro- 
duced in India after the completion of the ICMR study, which is expected in 
August 2005, we believe that confusion will result between the Essen regimen 
("1-1-1-1-1") used in the private sector and the TRC regimen ("2-2-2-0-1-1") used in 
the government sector. 
To overcome these caveats, we carefully reviewed the available data. We 
hypothesized that a dose on day 14 would be beneficial to retain the vaccina- 
tion schedule used in the Essen regimen, thus potentially avoiding some confu- 
sion, and that the day-90 booster in the TRC regimen could be omitted. As a 
result, we developed a new rabies vaccination regimen in which 0.1 mL of 
PCECV is administered ID at 2 body sites (deltoids) on days 0, 3, 7, 14, and 28 
("2-2-2-2-2"; the KIMS-ID regimen). 
The objective of this study was to compare the immunogenicity as well as 
local and systemic tolerability of the KIMS-ID regimen with those of the Essen 
IM regimen in healthy adult volunteers in India. 
MATERIALS AND METHODS 
This prospective, randomized, open-label, active-controlled, parallel-group, 
simulated postexposure gimen study was conducted at the Antirabies Clinic, 
Medical College, KIMS. The Good Clinical Practice guideline 15 was followed, 
and enrollment commenced after institutional ethics committee approval of 
the protocol was obtained. 
Inclusion and Exclusion Criteria 
After a screening physical examination, healthy volunteers of both sexes, aged 
___18 years, and willing to be available for 365-day follow-up were recruited from a 
pool of KIMS medical students and enrolled into the study after providing written 
informed consent to participate. 
Volunteers were excluded ifthey had received any rabies vaccine in the past; had 
a fever; had a history of any drug or alcohol abuse; had suspected or known HIV 
infection, immunodeficiency, or any autoimmune disorder; had a history of chloro- 
quine intake in the preceding 2 months; had an allergy to egg protein, neomycin, 
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tetracycline, or amphotericin B; were malnourished or receiving treatment with 
corticosteroids or immunosuppressive drugs; or were participating in any other 
study at the same time. Women who were pregnant or breast-feeding were excluded. 
Study Drug Administration 
Using True Epistat version 5.3 (Epistat Services, Richardson, Texas), a ran- 
dom assignment sequence was generated for 100 volunteers, balanced within 
10 blocks of 10 volunteers each, for an unbiased allotment of subjects to 1 of 
2 study groups: KIMS-ID regimen or Essen IM regimen (active control). 
The vaccine used in both study groups was PCECV* with Flury low egg pas- 
sage strain, which had a potency of 9.43 IU per milliliter of IM dose. The ID 
group was administered the vaccine at 0.1 mL injected in the left and right del- 
toid regions on days 0, 3, 7, 14, and 28, per the KIMS regimen. The IM group 
received 1 mL of the vaccine in 1 deltoid region on days 0, 3, 7, 14, and 28, per 
the Essen regimen. A trained physician administered all injections. 
Subjects were advised to report adverse effects (AEs) in person or by 
telephone to the investigating physician on each day of the 28-day period of 
vaccination. 
Estimation of Antibody Levels 
For the estimation of serum rabies virus-neutralizing antibody (RVNA) con- 
centrations, 5 mL of blood was drawn from the antecubital vein of all subjects on 
days 0, 14, 28, 90, 180, and 365. Hence, 6 blood samples were drawn from every 
subject. The serum was separated using centrifugation at 5000 rpm for 5 minutes 
at room temperature and stored at -20°C pending estimation of RVNA levels. 
The RVNA levels in the serum samples were estimated using the rapid fluores- 
cent focus inhibition test (RFFIT) at the Department of Neurovirology, Nation- 
al Institute of Mental Health and Neurosciences, Bangalore, India, as per the 
WHO-approved procedure, 16with some modifications. This test is 1 of 2 WHO- 
approved tests used for determining RVNA levels, and hence the level of protec- 
tion offered by a rabies vaccine. The other approved test is the mouse neutral- 
ization test (MNT). Our laboratory has found good correlation between the 
results of the MINT and RFFIT. Because the RFFIT is now well standardized in our 
laboratory, we did not test matched negative controls. However, known positive 
and negative serum samples were included each time the test was performed. 
The cell line used was baby hamster kidney 21 clone 13 (BHK 21 C13), obtained 
from the National Institute of Cell Science, Pune, India. The challenge virus used 
was challenge virus strain 11 (CVS-11), obtained from the Central Research 
Institute, Kasauli, India, and was adapted to grow in the same cell line. Briefly, 
increasing dilutions of the test and control sera were made in 96 well-tissue cul- 
ture plates, mixed with equal volumes of fluorescent focus dose 50 of CVS-11, 
and incubated at 37°C in a humid CO 2 incubator for 1 hour. The same volume of 
*Trademark: Rabipur ~ (Chiron Vaccines, Ankleshwar, India). 
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BHK 21 C13 cell suspension was added, with continued incubation for 48 hours. 
The monolayer of BHK 21 C13 cells formed were then stained using immuno- 
fluorescence with rabies fluorescein-isothiocyanate conjugate, obtained from 
the Central Research Institute. The highest dilution of serum, showing 50% 
inhibition of fluorescent foci, was used to estimate the RVNA concentration. 
Concentrations are expressed in international units, compared with the second 
international reference rabies immunoglobulin, which has a potency of 30 IU/mL, 
obtained from the National Institute for Biological Standards and Control, 
Hertfordshire, United Kingdom. A serum RVNA concentration ~0.5 IU/mL was 
considered adequate protection against rabies. 7
Statistical Analysis 
The data were analyzed using SPSS (SPSS Inc., Chicago, Illinois). The results 
are expressed as percentages or geometric means, with SDs or 95% Cls as 
appropriate. The log-likelihood ratio test and the Fisher exact est were applied. 
P values for statistical significance are given, with P < 0.05 considered statisti- 
cally significant. The log-likelihood ratio test was used for comparing the inci- 
dence of pain between the 2 regimens, and the Fisher exact test was used for 
comparing the incidence of itching between the 2 regimens. RVNA levels are 
expressed as geometric means (95% Cls) because the levels are measured using 
serial dilutions of the serum and the results follow geometric progression. 
RESULTS 
Ninety-one subjects were enrolled (54 men, 37 women; mean age, 20.9 [1.3] 
years [range, 18-23 years]; ID group, 45 subjects; IM group, 46 subjects). All of 
the subjects completed the study. The demographic profile of the subjects is 
given in Table II. Five subjects had allergies, as follows: sulfonamides (3), ceti- 
rizine (1), ampicillin (1), cephalosporins (1), and pollens (1). Two of these sub- 
jects had allergies to >1 substance. 
Immunogenicity 
None of the subjects in either treatment group had a detectable serum RVNA 
concentration on study day 0, which indicated that none had ever received 
rabies vaccination. From day 14 to study end, all subjects had RVNA concentra- 
tions ~0.5 IU/mL (Table III). The mean RVNA concentration i the ID group was 
approximately two thirds that of the IM group from days 14 to 365 (all, P < 0.001). 
Tolerability 
Pain at the injection site was reported in 2/225 (0.9%) vaccination injections 
in the ID group (all moderate) and in 10/230 (4.3%) injections in the IM group 
(6 mild, 1 moderate, and 3 severe) (Table IV). This difference was statistically 
significant (P < 0.006 [log-likelihood ratio test]). Itching at the injection site was 
reported in 5/225 (2.2%) injections in the ID group, and in none of the injections 
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Table II. Demographic and clinical characteristics of the study subJects (N = 91).* 
ID Group IM Group 
Characteristic (n = 45) t (n = 46) ~ 
Age, mean (SD), y 20.84 (1.48) 21.02 (1.1 6) 
Sex, no. (%) 
Male 
Female 
Weight, mean (SD), kg 
Height, mean (SD), cm 
History of allergies, no. (%) 
26 (57.8) 28 (60.9) 
19 (42.2) 1 8 (39.1) 
60.89 (10.04) 59.72 (11.30) 
1 67.13 (8.84) 1 65.33 (8.36) 
2 (4.4) 3 (6.5) 
ID = intradermal administration. 
*No statistically significant between-group differences were found. 
tThis group received ID purified chick emb~,o cell vaccine (PCECV), 0.1 mL at 2 body sites (right and left 
deltoid), on days 0, 3, 7, 14, and 28. 
~This group received IM PCECV, 1 mL at 1 body site (deltoid), on days 0, 3, 7, 14, and 28. 
Table III. Rabies virus neutralizing antibody response in subjects receiving intrader- 
real (ID) purified chick embryo cell vaccine (PCECV) (n = 45)* or IM PCECV 
(n = 46) t throughout  the study. 
Study ID Group, IM Group, Ratio 
Day GM (95% CI) GM (95% CI) (95% Cl)* P of Ratio 
1 4 4.1 7 (3.69-4.71) 6.89 (6.33-7.49) 0.605 (0.523-0.700) <0.001 
28 7.60 (6.93-8.33) 11.53 (10.82-1 2.27) 0.659 (0.591-0.736) <0.001 
90 4.79 (4.26-5.38) 6.99 (6.37-7.67) 0.685 (0.591-0.793) <0.001 
180 2.00 (1.74-2.30) 3.29 (2.93-3.69) 0.608 (0.510-0.726) <0.001 
365 1.03 (0.88-1.21) 1.58 (1.38-1.81) 0.654 (0.534-0.802) <0.001 
GM = geometric mean. 
*This group received ID PCECV, 0.1 mL at 2 body sites (right and left deltoids), on days 0, 3, 7, 14, 
and 28. 
tThis group received IM PCECV, 1 mL at 1 body site (deltoid), on days 0, 3, 7, 14, and 28. 
~Log-likelihood ratio test. 
in the IM group. This difference was also statistically significant (P = 0.026 
[Fisher exact test]). All AEs were transient and resolved without the need for 
medication. No other AEs were reported, including fever, headache, myalgia, 
and arthralgia. 
DISCUSSION 
Rabies is fatal in nearly 100% of cases, even today. However, rabies vaccines 
administered as either preexposure or postexposure prophylaxis can be life- 
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Table IV. Frequency of local adverse events (AEs) (N = 91). Values are presented as 
number (%) of injections. 
ID Group* IM Group t 
AE (n = 225 injections) (n = 230 injections) P 
Pain 
Mild 0 6 (2.6) - 
Moderate 2 (0.9) 1 (0.4) - 
Severe 0 3 (1.3) - 
Total 2 (0.9) 10 (4.3) <0.006 ~ 
Itching 5 (2.2) 0 0.026§ 
ID = intradermal administration. 
*This group received ID purified chick embryo cell vaccine (PCECV), 0.1 mL at 2 body sites (right and 
left deltoids), on days 0, 3, 7, 14, and 28. 
tThis group received IM PCECV, 1 mL at 1 body site (deltoid), on days 0, 3, 7, 14, and 28. 
~Log-likelihood ratio test. 
§Fisher exact test. 
saving. In India, the CCVs--PCECV, PVRV, HDCV, and PDEV--have been ap- 
proved by the DCGI for use by the IM route following the Essen regimen. 
However, the cost of 1 dose of IM CCV is $4 to $6, which is not affordable by 
most people living in India. 17 Although PCECV and PVRV are WHO approved for 
ID administration, 18 these CCVs have not been approved for ID administration by
the DCGI. The ICMR is investigating the feasibility of administering PCECV, PVRV, 
and PDEV by the ID route following the original TRC regimen ("2-2-2-0-1-1") 
(unpublished ocument, ICMR, 2004). Even if the results are favorable, we 
opine that the TRC regimen, which is expected to replace NTV used in the gov- 
ernment sector, will lead to confusion because no vaccine is administered on 
day 14, but a booster dose is given on day 90. Because the day-90 booster has 
been omitted from the Essen IM regimen, we hypothesized that the booster 
dose might not be required in the ID regimen. Some studies have shown a long- 
term protective immune response with PCECV and PVRV administered using 
the TRC regimen. 19,2° We tested PCECV given ID using a new "2-2-2-2-2" regimen 
over a period of 1 year. This regimen might facilitate crossover of vaccinees 
from the ID regimen in the government sector to the IM regimen in the private 
sector. However, the WHO recommends continuation of one type of adminis- 
tration (ID or IM) throughout the entire vaccination process. 
The potency of the PCECV produced in India is high, with the batch used in 
the present study being 9.43 IU per IM dose of vaccine, compared with the stan- 
dard minimum, ___2.5 IU per IM dose. However, one study showed an adequate 
immune response in all subjects using a vaccine with a potency as low as 0.25 IU 
per ID dose. 21 The significantly higher concentrations of RVNA found with IM 
PCECV in the present study were likely due to a higher antigenic stimulus corn- 
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pared with the ID route but are not considered clinically significant because the 
levels were higher than the WHO-recommended l vel of a0.5 IU/mL. 
The cost of a complete course of NTV used for PEP is ~$522; that of the Essen 
IM regimen (total PCECV, 5 mL) is -$25, which is unaffordable by most peo- 
ple living in India. 17 Today, the WHO recommends the TRC ID regimen is (total 
PCECV, 0.8 mL), which costs ~$4, but this route is not yet approved in India. A 
complete course using the KIMS-ID regimen comprises a total of 1 vial contain- 
ing 1 mL of PCECV or 2 vials containing 0.5 mL of PVRV. Although the KIMS-ID 
regimen would cost marginally more compared with the TRC regimen, we 
believe that it would prevent confusion by maintaining the Essen IM schedule 
and potentially increase compliance. 
To manage the large number of bite victims in India, some time-bound plans 
are needed so that the incidence of human rabies can be decreased. Introducing 
the ID route of administration for rabies vaccines to the Indian population in 
government-managed hospitals could help to achieve this objective. After addi- 
tional research, the KIMS-ID regimen might be considered one of the future 
options for ID rabies vaccines in India. Future studies in larger and more diverse 
populations, including people who are immune compromised, elderly popula- 
tions, and children, are needed. 
CONCLUSIONS 
The new 2-site PCECV PEP rabies vaccine administered using the KIMS-ID regi- 
men was immunologically efficacious for 365 days and well tolerated in this 
study in healthy volunteers. Adequate RVNA levels were maintained with this 
vaccine from days 14 to 365, although these levels were significantly ower than 
those achieved in the group receiving IM PCECV by the Essen regimen. 
ACKNOWLEDGMENTS 
The voluntary participation ofthe medical students i gratefully acknowledged. 
The assistance of A.S. Nanivadekar, MD, Gangaboriah B. Andanaiah, PhD, and 
Annapurna Rao, PhD, in providing statistical input is sincerely acknowledged. 
The authors also thank Claudius Malerczyk, MD, for reviewing the manuscript 
and suggesting improvements. 
REFERENCES 
1. World Health Organization, Department ofCommunicable Disease Surveillance and 
Response. World Survey for Rabies No. 33 for the year 1997 [WHO Web site]. Geneva, 
Switzerland: WHO; 1999. Publication o. WHO/CDS/CSR[APH/99.4. Available at: www. 
who.int. Accessed June 1, 2005. 
2. Association for the Prevention and Control of Rabies in India. Assessing the burden 
of rabies in India: A national multicentric survey. Progress Report. 2003. Available at: 
www.vet.ed.ac.uk. Accessed June 1, 2005. 
332 
M.K. Sudarshan et al. 
3. Bhalla S, Nagar S. Analysis of complications of nervous tissue anti-rabies vaccines in 
Jamnagar, Guj arat, lnd J lnt Med. 2001 ;11 (Suppl): 13-16. 
4. Singh S, Kumar T. Rabies vaccines--An overview. JAPCRI. 1999;1'.14-20. 
5. World Health Organization, Expert Committee on Rabies. 7th report [CDC Web site]. 
Geneva, Switzerland: WHO; 1984. Technical Report Series 709. Available at: www. 
cdc.gov/mmwr. Accessed June 1, 2005. 
6. Rabies prevention--United States, 1984. MMWR Morb Mortal Wkly Rep. 1984;33:393- 
402,407-408. 
7. World Health Organization, Expert Committee on Rabies. 8th report [CDC Web site]. 
Geneva, Switzerland: WHO; 1992. Technical Report Series 824. Available at: www.cdc. 
gov/mmwr. Accessed June 1, 2005. 
8. Chutivongse S, Wilde H, Supich C, et al. Postexposure prophylaxis for rabies with 
antiserum and intradermal vaccination. Lancet. 1990;335:896-898. 
9. Briggs D J, Banzhoff A, Nicolay U, et al. Antibody response of patients after postexpo- 
sure rabies vaccination with small intradermal doses of purified chick embryo cell 
vaccine or purified Vero cell rabies vaccine. Bull World Health Organ. 2000;78:693-698. 
10. Madhusudana SN, Anand NP, Shamsundar R. Evaluation of two intradermal vaccina- 
tion regimens using purified chick embryo cell vaccine for postexposure prophylaxis 
for rabies. Natl Med J lndia. 2001;14:145-147. 
11. Jaiiaroensup W, Lang J, Thipkong P, et al. Safety and efficacy of purified Vero cell 
rabies vaccine given intramuscularly and intradermally. (Results of a prospective 
randomized trial). Vaccine. 1998;16'.1559-1562. 
12. Association for Prevention and Control of Rabies in India. In'. Proceedings of the Na- 
tional Seminar on Intradermal Rabies Vaccination. February 25, 2003; Bangalore, India. 
13. Khawplod P, Tantawichien T, Wilde H, et al. Use of rabies vaccines after reconstitu- 
tion and storage. Clin Infect Dis. 2002;34:404-406. 
14. World Health Organization. WHO Expert Consultation on Rabies. Technical Report 
Series 931 [WHO Web site]. Geneva, Switzerland'. WHO; 2004. Available at'. www.who. 
int/rabies. Accessed June 1, 2005. 
15. European Agency for the Evaluation of Medicinal Products, International Conference 
on Harmonisation-World Health Organization. Guideline for Good Clinical Practice 
[EMEA Web site]. ICH Topic E6. Geneva, Switzerland: WHO; 2002. Available at: 
http://www.emea.eu.int. Accessed June 1, 2005. 
16. Smith JS, Yager PA, Baer GM. A rapid fluorescent focus inhibition test (RFFIT) for 
determining rabies virus neutralizing antibody. In: Meslin F-X, Kaplan MM, 
Koprowsky H, eds. Laboratory Techniques in Rabies. 4th ed. Geneva, Switzerland'. 
World Health Organization; 1996'.181-192. 
17. Madhusudana SN, Sanjay TV, Mahendra BJ, Suja MS. Simulated post-exposure abies 
vaccination with purified chick embryo cell vaccine using a modified Thai Red Cross 
regimen, lnt J lnfect Dis. 2004;8:175-179. 
18. World Health Organization, Department of Communicable Disease Surveillance and 
Response. WHO Recommendations on Rabies Post-Exposure Treatment and the 
Correct Technique of Intradermal Immunization Against Rabies [WHO Web site]. 
Geneva, Switzerland: WHO; 1988. Publication no. WHO/EMC/ZOO 96.6. Available at: 
www.who.int/en. Accessed August 1, 2005. 
19. Sabchareon A, Chantavanich P, Pasuralertsakul S, et al. Persistence of antibodies in 
children after intradermal or intramuscular dministration of preexposure primary 
and booster immunizations with purified Veto cell rabies vaccine, Pediatr Infect Dis J, 
1998;17:1001-1007. 
333 
CURRENT THERAPEUTIC RESEARCH 
20. Yang Y, Zhang J, An experimental study on the endurance of immunologic memory 
of intradermal micro-injection with rabies vaccine and boosting immune effect. 
J Epidemiol. 1999;9:209-215. 
21. Beran J, Honegr K, Banzhoff A, Malerczyk C. Potency requirements of rabies vaccines 
administered intradermally using the Thai Red Cross regimen'. Investigation of the 
immunogeniciW of serially diluted purified chick embryo cell rabies vaccine. 
Vaccine. 2005;23:3902-3907. 
22. Sudarshan MK, Mahendra BJ, Ashwath Narayana DH. A cost accounting analysis of 
production of Semple (sheep brain) vaccine in India. Journal of Association for 
Prevention and Control of Rabies in India. 2002;4:40-41. 
Address correspondence to: M.K. Sudarshan, MD, Department of Community 
Medicine, Kempegowda Institute of Medical Sciences, Bangalore 560004, India. 
E-mail: mksudarshan~vsnl.com 
334 
